Researchers have identified a new genetic mutation for amyotrophic lateral sclerosis (ALS), opening the door to future targeted therapies.
Some children who are accurately diagnosed in early childhood with autism lose the symptoms and the diagnosis as they grow older, a study supported by the National Institutes of Health has confirmed.
Researchers discovered a way to stimulate the brain’s natural defense mechanisms in mice with Alzheimer’s disease symptoms. This major breakthrough opens the door to the development of a treatment for Alzheimer’s disease and a vaccine to prevent the illness.
Scientists report researchers are now on the threshold of human application of stem cell therapies for a class of neurological diseases known as myelin disorders – a long list of diseases that include conditions such as multiple sclerosis, white matter stroke, cerebral palsy, certain dementias, and rare but fatal childhood disorders called pediatric leukodystrophies.
Researchers found a key difference in the brains of people with Alzheimer’s disease and those who are cognitively normal but still have brain plaques that characterize this type of dementia.
The brain’s key “breeder” cells secrete substances that boost the numbers and strength of critical brain-based immune cells believed to play a vital role in brain health. This finding adds a new dimension to our understanding of how resident stem cells and stem cell transplants may improve brain function.
Stem cell study may help to unravel how a genetic mutation leads to Parkinson’s symptoms. By reprogramming skin cells from Parkinson’s disease patients with a known genetic mutation, researchers identified damage to neural stem cells as a powerful player in Parkinson’s disease.
An inexpensive, five-minute eye scan can accurately assess the amount of brain damage in people with the debilitating autoimmune disorder multiple sclerosis (MS), and offer clues about how quickly the disease is progressing.
Electrical stimulation using extradural electrodes—placed underneath the skull but not implanted in the brain, is a safe approach with meaningful benefits for patients with Parkinson’s disease according to new research.
An international research team revealed the atomic‐level structure of the human peptidase enzyme meprin β (beta).